Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of June 2026, with a report date of June 18, 2026. The filing primarily announces a private placement offering and a significant commercial milestone regarding the company's breast cancer cryoablation technology.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $5.5 million expected from the private placement.
- Offering Price: $2.9999 per Pre-Funded Warrant and accompanying Warrants.
- Securities Issued: 1,833,334 Pre-Funded Warrants, 1,833,334 Series D Warrants, and 1,833,334 Series E Warrants.
- Exercise Prices: Pre-Funded Warrants at $0.0001; Series D and E Warrants at $3.00.
- Placement Fees: 7.0% cash fee to the placement agent (A.G.P.), reduced to 3.0% for certain mutually agreed investors.
- Expense Reimbursement: Up to $50,000 for legal and other expenses.
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for the period. It focuses on the capital raise transaction.
Material Changes and Commercial Developments
- Commercial Growth: The company reported a 70% growth in its active U.S. commercial install base for breast cancer cryoablation following FDA clearance.
- Warrant Amendments: Existing Series B and Series C warrants (originally issued March 27, 2026) are being amended to reduce the exercise price from $16.50 to $3.00 per share. Expiration dates are extended to June 18, 2031 (Series B) and June 18, 2027 (Series C).
- Investor Profile: The offering is priced at a premium to the market price and involves a single healthcare-focused institutional investor.
Guidance, Risks, and Contingencies
- Closing Conditions: The offering closing is expected on or about June 18, 2026, subject to customary conditions.
- Shareholder Approval: The effectiveness of the warrant amendments is contingent upon shareholder approval.
- Registration Requirements: The company must file a resale registration statement within 10 trading days and use commercially reasonable efforts to have it effective within 30 to 60 days.
- Lock-Up Agreements: Directors and executive officers are locked up for 30 days following the effective date of the resale registration statement.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to inherent uncertainties.
Investor Verification Checklist
- Confirm the final closing date and actual net proceeds after fees.
- Verify shareholder approval status for the warrant amendments (Series B and C).
- Monitor the filing and effectiveness of the resale registration statement (Form S-3 or equivalent).
- Review the specific terms of the "mutually agreed investors" clause regarding the reduced 3.0% placement fee.
- Assess the impact of the 70% install base growth on future revenue projections in upcoming earnings reports.